US75120L1008 - Common Stock
RALLYBIO CORP
NASDAQ:RLYB (3/27/2024, 8:00:01 PM)
After market: 1.59 0 (0%)1.59
+0.12 (+8.16%)
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 44 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease that impacts fetuses and newborns. Its pipeline includes RLYB212, RLYB116, RLYB114, RLYB331 and ENPP1 Program. RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for the prevention of HPA-1a maternal alloimmunization and the occurrence of FNAIT. Its advanced product candidate, RLYB116, is an inhibitor of complement component 5 (C5) used to treat complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and others. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule designed for the treatment of complement-mediated ophthalmic diseases.
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT
P: 12038593820
CEO: Martin W. Mackay
Employees: 44
Website: https://rallybio.com/
Jefferies has downgraded Rallybio (RLYB) to hold, citing a lack of near-term pipeline catalysts and slow development of its lead drug program.
Rallybio (RLYB) shares rose 13% early Tuesday after the company announced it was cutting 45% of its workforce to streamline its drug portfolio and extend its ca
Here you can normally see the latest stock twits on RLYB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: